Adjuvant chemotherapy of non-small-cell lung cancer
نویسندگان
چکیده
منابع مشابه
Adjuvant chemotherapy of non-small-cell lung cancer
Approximately 25-30% of patients with non-small cell lung cancer (NSCLC) present with early stage disease and undergo surgery with curative intent. Despite complete tumor resection, many of these patients will develop systemic relapses with or without local relapses and will eventually die from the disease. Systemic relapses occur due to the presence of micro-metastatic disease at the time of s...
متن کاملAdjuvant chemotherapy for completely resected non-small-cell lung cancer.
PURPOSE To conduct a systematic review and to evaluate the impact of postoperative adjuvant chemotherapy on the survival of patients with completely resected non-small cell lung cancer. METHODS Relevant randomized trials and meta-analyses, published as articles or abstracts, were identified through electronic and hand searches by two reviewers. RESULTS Seven meta-analyses and 26 randomized ...
متن کاملAdjuvant chemotherapy for non-small cell lung cancer.
BACKGROUND Adjuvant chemotherapy (ACT) is known to improve survival in patients with early-stage non-small cell lung cancer. Herein, we describe chemotherapy regimens used, dose modifications, survival, and treatment-related toxicity in the general population. METHODS All cases of non-small cell lung cancer diagnosed in Ontario in the period 2004-2006 who underwent surgical resection (n = 335...
متن کاملAdjuvant chemotherapy for resected non-small cell lung cancer.
Surgery remains the mainstay of therapy for early stage non-small cell lung cancer (NSCLC), but even for stage IA, disease relapse rates remain as high as 30%. Patients with completely resected (R0) N1 disease have about a 50% chance of relapse. In the past 5 years, the benefit of adjuvant chemotherapy has finally been demonstrated for patients with lung cancer. Improvements of 5% to 10% 5-year...
متن کاملAdjuvant Chemotherapy for Resected Non–Small-Cell Lung Cancer
Because of the high rate of distant disease recurrence, the 5-year survival of patients who have undergone complete surgical resection of localized non–small-cell lung cancer (NSCLC) is approximately 50%. Initial results from early studies of adjuvant postoperative chemotherapy reported an adverse effect of alkylating agent and older chemotherapy regimens on survival. Cisplatin-based combinatio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Cancer Supplements
سال: 2013
ISSN: 1359-6349
DOI: 10.1016/j.ejcsup.2013.07.024